Thu, 07 Aug 2025
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.
>>
Terms of Use | Privacy Policy | Manage Cookies+ | Ad Choices | Accessibility & CC | About | Newsletters | Transcripts
Business News Top © 2024-2025